
Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365 and 10,456,211) relate to fundamental technologies and methods embedded in UNiD ASI, primarily methods, systems and devices for designing and manufacturing a spinal rod, and also methods and apparatus for spinal reconstructive surgery and measurement of spinal length and intervertebral spacing, tension and rotation.
CEO Denys Sournac said, “With over 5,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need. The new U.S. patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its leading position in the marketplace that is now obviously evolving into this direction.”
Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365...
Medicrea was issued seven additional patents related to its proprietary UNiD™ ASI (Adaptive Spine Intelligence) technology platform that augments procedures with tools for data management, artificial intelligence and predictive modeling.
The U.S. patents (10,441,363; 10,433,912; 10,420,615; 10,433,913; 10,426,553; 10,413,365 and 10,456,211) relate to fundamental technologies and methods embedded in UNiD ASI, primarily methods, systems and devices for designing and manufacturing a spinal rod, and also methods and apparatus for spinal reconstructive surgery and measurement of spinal length and intervertebral spacing, tension and rotation.
CEO Denys Sournac said, “With over 5,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need. The new U.S. patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its leading position in the marketplace that is now obviously evolving into this direction.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.